News & Publications

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

  • 13

    Nov

    18

  • KemPharm Enhances Pipeline with the Addition of KP879, a Potential New Treatment for Stimulant Use Disorder

  • 08

    Nov

    18

  • KemPharm, Inc. Reports Third Quarter 2018 Results

  • 01

    Nov

    18

  • KemPharm to Report Third Quarter 2018 Results

  • 30

    Oct

    18

  • KemPharm Enters Into License Agreement with KVK Tech for the Commercialization of APADAZ® 

  • 24

    Oct

    18

  • KemPharm Presents Data from Intranasal and Intravenous Human Abuse Potential Trials of KP415 Prodrug at the American Academy of Child & Adolescent Psychiatry Meeting

  • 23

    Oct

    18

  • KemPharm and twoXAR Announce Technology Collaboration to Develop Prodrug-Based Therapies for Multiple Indications

  • 11

    Oct

    18

  • KemPharm Provides Highlights from KOL Investor Event Focused on the ADHD Treatment Landscape

  • 05

    Oct

    18

  • KemPharm Announces Pricing of Public Offering of Common Stock

  • 04

    Oct

    18

  • KemPharm Announces Proposed Public Offering of Common Stock

  • 03

    Oct

    18

  • KemPharm to Host KOL Investor Event Focused on the ADHD Treatment Landscape

  • 17

    Sep

    18

  • KemPharm Announces Positive Topline Results from Intranasal Human Abuse Potential Trial of KP415 Prodrug

  • 11

    Sep

    18

  • KemPharm Announces Positive Topline Results from Oral Human Abuse Potential Trial of KP415 Prodrug